Timothy Walbert was appointed chair of the board of directors of Latigo Biotherapeutics, a clinical-stage biotechnology company developing best-in-class non-opioid pain medicines.
Current Issue
//SPRING 2025
Feature
A Boundless Legacy
With the help of unprecedented levels of support from volunteers, Boundless: The Campaign for […]
Feature
On Common Ground
Classes that bring together Muhlenberg students and incarcerated students — Inside-Out courses […]
//Profiles
Past Issues
Go to Muhlenberg.edu
© 2024 Muhlenberg College